Supplementary Table 2: Pharmacogenetic loci for rosuvastatin are associated with intima-media thickness change and coronary artery disease risk.docx

Supplementary Table 2. Call rate for genotyped SNPs and number of cases, included into analyses of associations with total cholesterol and low-density lipoprotein cholesterol change, baseline carotid intima-media thickness, and its change during rosuvastatin therapy.